Publications by authors named "Masaki Arai"
Unobtrusive in-car measurement of physiological signals on the road.
Annu Int Conf IEEE Eng Med Biol Soc
July 2024
This paper presents a system for unobtrusive monitoring of physiological signals of a car driver. It comprises three sensor modalities that conduct measurements through clothes: a Magnetic induction sensor for respiration monitoring, and a reflective Photoplethysmograph as well as a capacitive Electrocardiograph for cardiac monitoring. The sensor system has been attached to the driver seat of a car and a healthy subject was asked to drive through the busy streets of Tokyo while monitored.
View Article and Find Full Text PDFBackground: This study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.
Methods: This was a retrospective, observational, longitudinal study of patients with PD (≥30 years, ICD-10: G20 excluding Parkinson's syndrome) from three Japanese nationwide healthcare claim databases. Prescription drugs were tabulated using database receipt codes.
Article Synopsis
- The study examines the impact of the COVID-19 pandemic on patients with Parkinson's disease (PD) and their caregivers in Japan, focusing on changes in behaviors, symptoms, and caregiver burden.
- An observational survey analyzed responses from nearly 2,000 patients and caregivers, revealing that many patients experienced decreased mobility and worsened symptoms during the pandemic.
- The findings highlight the need for additional support for patients and caregivers during health crises to alleviate the increased burden of care due to worsening symptoms.
Objective Although diagnostic criteria of Parkinson's disease (PD) have been established, the details of the process by which patients notice symptoms, visit a physician, and receive a diagnosis of PD is unclear. We therefore explored factors influencing latency in diagnosing PD. Methods We performed an internet-based survey of patients with PD and their families as well as physicians treating patients with PD to identify any diagnostic latency and its determinants.
View Article and Find Full Text PDFBackground: Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor used as monotherapy in early Parkinson's disease and as an adjunct therapy to levodopa in Parkinson's disease with motor fluctuations.
Objectives: This meta-analysis aimed to provide updated evidence on the efficacy for motor and nonmotor symptoms and the safety of rasagiline/levodopa versus levodopa in patients with Parkinson's disease experiencing motor fluctuations.
Methods: A systematic literature search was conducted (January 18-19, 2021) using PubMed, Cochrane Library, EMBASE, Web of Science, and Google Scholar to identify randomized controlled trials comparing rasagiline/levodopa versus placebo/levodopa in patients with Parkinson's disease experiencing motor fluctuations.
Objective: This study aimed to gain an understanding of patient and physician satisfaction with overall treatment and routine consultations for Parkinson's disease in clinical practice.
Methods: This observational, cross-sectional, web-based survey was conducted in Japan from February to March 2019. Eligible patients with Parkinson's disease ( = 186) and physicians who treat patients with Parkinson's disease ( = 331) were asked to evaluate their satisfaction with treatment, consultation, symptom control, and use of a symptom diary.
Background: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain, a 6-question subset of the PDQ-39 which is considered to reflect the emotional aspects of the disease-specific HRQoL, when treated with rasagiline, than placebo, in both a monotherapy clinical trial (NCT02337725) and an adjunctive therapy clinical trial in patients with wearing-off phenomena (NCT02337738).
Objective: To investigate how rasagiline exerts its effect on the PDQ-39 emotional well-being domain in Japanese patients with Parkinson's disease.
Introduction: Parkinson's disease (PD) treatment should follow guidelines and be tailored to each patient. Large database analyses can provide insights into prescribing patterns.
Methods: Retrospective, cross-sectional study of patients (≥30 years) with PD diagnosis (ICD-10; schizophrenia/cerebrovascular disease excluded) using health insurance claims data (April 2008-December 2016) from the Japan Medical Data Vision database.
Background: Adherence to the 2011 Japanese guidelines for treatment of Parkinson's disease (PD) in real-life practice is unknown.
Methods: In this retrospective longitudinal observational study, we examined patterns and trends in anti-PD drug prescriptions in 20,936 patients (≥30 years of age with newly diagnosed PD [International Classification of Diseases-Tenth code G20 or PD Hoehn and Yahr scale 1-5] and one or more prescriptions) using nationwide registry data between 2008 and 2016. Data are presented as descriptive statistics.